For every 39-mg/dL reduction in LDL, there was a 24% (95% CI, 5 39) reduction in the risk of stroke in participants with an estimated 5-year risk of major vascular events <10%, which was similar to the rela- tionship seen in higher-risk categories. Similarly, another meta- analysis, which included 14 trials reporting stroke outcomes in patients with an estimated 10-year risk of cardiovascular events of <20%, found that the RR of stroke was significantly lower among statin recipients than among control subjects (RR, In addition, in Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), statin treatment reduced the inci- dence of fatal and nonfatal stroke compared with placebo (HR, 0.52; 95% CI, 0.34 0.79) in healthy men and women with LDL cholesterol levels <130 mg/dL and high-sensitivity C-reactive protein (hs-CRP) levels 2.0 mg/L.160 Concerns about lowering of LDL cholesterol by statin therapy increasing the risk of hemorrhagic stroke are not sup- ported. One meta-analysis of 31 trials comparing statin ther- apy with a control reported that statin therapy decreased total stroke (OR, 0.84; 95% CI, 0.78 0.91) and found no difference in the incidence of ICH (OR, 1.08; 95% CI, 0.88 1.32).161 These findings are consistent with another meta-analysis that included 23 randomized trials and found that statins were not associated with an increased risk of ICH (RR, 1.10; 95% CI, The intensity of cholesterol lowering did not correlate with risk of ICH. The beneficial effect of statins on ischemic stroke is most likely related to their capacity to reduce progression or to induce regression of atherosclerosis. 